| |
Are you thinking about launching a study? Or are you in the middle of managing a biopharma project? Learn more about the major risks surrounding your work and the best ways to manage your project for success. Download the App Note here. 
|
|
Today's Big NewsNov 2, 2022 |
| By Gabrielle Masson Exelixis has penned two separate deals, one with Cybrexa Therapeutics and one with Sairopa, offering up to $937 million-plus in biobucks. |
|
|
|
By Max Bayer Nearly three months after pausing dosing, uniQure's trial in patients with Huntington's disease is set to resume. The trial was paused after three patients treated with the gene therapy were hospitalized. |
By James Waldron The last few weeks have seen GSK and Pfizer locked in a neck-and-neck race to see who can get their respiratory syncytial virus (RSV) to market first. Now, it looks like GSK may have the edge in the U.S., securing priority review status from the FDA and an estimated decision date of May 3. |
Sponsored by Fortress Biotech With 9 marketed products and 20 clinical programs, Fortress Bio’s business model is designed to decrease risk and expense while creating a regular flow of value-creating events for shareholders. |
By Annalee Armstrong Metabolic-disorder-focused OrsoBio launched Tuesday with Gilead alums Mani Subramanian, M.D., in the CEO seat and Rob Myers, M.D., serving as chief medical officer. |
Sponsored by By: Fierce Biotech Fierce Biotech sits down with biotech and drug development leaders as they discuss the latest breakthroughs and innovations driving the life sciences industry. These videos explore what's next for the biotech industry and how companies are delivering value to patients and customers in today's evolving healthcare landscape. |
By James Waldron Another week, another layoff announcement. This time it’s Surface Oncology, which has cited the decision to pause work on anti-tumor antibody SRF617 as the reason for waving goodbye to a fifth of its staff. |
By Kevin Dunleavy Uptake of Pfizer’s omicron-adjusted COVID-19 booster may be progressing slowly, but after a surprisingly strong quarter, the company has bumped up its projection for COVID vaccine sales for the year by $2 billion to a total of $34 billion. Yet analysts aren't persuaded. |
By Andrea Park As the FDA convenes an advisory committee meeting to discuss recent studies showing that many pulse oximeters are less effective when used on patients with darker skin, BioIntelliSense is getting a head start on addressing the issue. |
By Heather Landi CVS reported a quarterly loss of more than $3 billion to cover its share of a global opioid settlement, but its third-quarter earnings blew past Wall Street estimates. |
By Ben Adams FDA Commissioner Robert Califf, M.D., used to be a quiet, highly reserved figure on Twitter during his first tenure as the head of the agency. But the second time around, he’s fully embraced the social media platform, and is now imploring users to stay on the site. |
Fierce podcasts Don't miss an episode |
| This week on “The Top Line,” we dig into rumors of a shaky relationship between Biogen and Eisai. We also chat about AZ’s ability to finally tout the approval of an asset that’s seen many failures over the years. |
|
|---|
|
|
|
Tuesday, November 8, 2022 | 12:30pm ET / 9:30am PT As a partner in the overall health ecosystem, Myriad Genetics is combining de-identified genetic data with indications, phenotypes, and outcomes to power the next generation of precision medicine advancements. Register now. 
|
|
Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
Whitepaper Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
Research Learn more about adaptive ascending dose escalation designs and considerations for determining the optimal approach to meet your drug development objectives Sponsored by: Allucent |
Whitepaper This paper outlines how gene therapy supply chains are different from traditional biopharma products, as well as the factors that are essential to success. Sponsored by: Blue Matter |
Video Revolutionize your monoclonal antibody (mAb) manufacturing process with the Gibco™️ Efficient-Pro™️ Medium and Feed System. Watch our how-to video. Sponsored by: Thermo Fisher Scientific |
eBook In this free guide, explore how Cloud Computing is enabling emerging biopharma organizations to decrease time-to-discovery in pursuit of breakthrough treatment modalities. Sponsored by: RCH Solutions |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored By: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored By: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| |
|
